Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4244/EIJV14I10A191 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of drug-coated balloon for vascular luminal dilatational remodeling after balloon angioplasty in intracranial atherosclerotic stenosis - a retrospective cohort study.
J Neurointerv Surg
January 2025
Department of Cerebrovascular Disease, Zhengzhou University People's Hospital, Henan Provincial People's Hospital; Henan Provincial Cerebrovascular Interventional Innovation Engineering Technology Research Center, Henan International Joint Laboratory of Cerebrovascular Disease, Zhengzhou, Henan, China
Objective: This study aimed to examine the effect of drug-coated balloons (DCBs) on vascular luminal dilatational remodeling (VLDR) following simple balloon angioplasty.
Methods: A retrospective cohort study was conducted using data from patients diagnosed with intracranial atherosclerotic stenosis (ICAS), who were treated exclusively with balloon angioplasty at Henan Provincial People's Hospital between June 2019 and April 2023. Inverse probability weighting (IPW) was used to create balanced cohorts of patients who underwent drug-coated balloon angioplasty (DCBA) and plain old balloon angioplasty (POBA).
Efficacy and Safety of Sirolimus-Coated Balloon Angioplasty in De Novo Lesions in Large Coronary Vessels: A Propensity Score-Matched Study.
Catheter Cardiovasc Interv
January 2025
Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Background: Evidence regarding drug-coated balloon (DCB)-only angioplasty in de novo lesions of large vessels is still limited and mainly focused on paclitaxel-coated balloon. We aimed to analyze the safety and efficacy of sirolimus-coated balloon (SCB)-only angioplasty in de novo lesions in large vessels compared to drug-eluting stent (DES).
Methods: In this retrospective, dual-center, case-control study, we enrolled all consecutive patients treated between January 2022 and January 2024 with SCB-only angioplasty in de novo lesion in large vessel (> 2.
Paclitaxel-Coated Balloon for the Management of In-Stent Coronary Restenosis: An Updated Meta-Analysis and Trial Sequential Analysis.
Catheter Cardiovasc Interv
January 2025
Department of Medicine, Federal University of Goiás, Goiânia, Brazil.
Background: Drug-coated balloons present a potentially advantageous therapeutic approach for managing coronary in-stent restenosis (ISR). However, the comparative benefits of paclitaxel-coated balloons (PCBs) over uncoated balloons (UCBs) remain unclear.
Aims: We conducted a systematic review and meta-analysis to evaluate and compare the clinical outcomes of patients treated with PCBs and UCBs.
Recurrent drug eluting stent, in-stent restenosis (DES-ISR): Epidemiology, pathophysiology & treatment.
Prog Cardiovasc Dis
January 2025
Division of Cardiovascular Medicine, Department of Medicine, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22909, United States of America. Electronic address:
Coronary artery in-stent restenosis (ISR) is driven by neointimal hyperplasia and neoatherosclerosis in previously placed stents. Drug eluting stents (DES) have been adopted as first line therapy for the initial episode of ISR. However, recurrent ISR has limited durable salvage options.
View Article and Find Full Text PDFDrug-Coated Balloons versus Drug-Eluting Stents for the Treatment of De Novo Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials.
Rev Cardiovasc Med
December 2024
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 100069 Beijing, China.
Background: Because of the limitations in new-generation drug-eluting stents (DES), treatments advocating for non-stents with a drug-coated balloon (DCB) is now of great interest. Here, we conducted a meta-analysis to testify whether a DCB was more effective and safer than a DES in treating de novo coronary artery disease (CAD).
Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science to obtain high-quality trials comparing DCB with DES for the treatment of de novo CAD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!